Clinical Trial Update: An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI) [Phase 3]

View source ↗

Summary

Phase 3 trial update for Ixmyelocel-T in patients with Critical Limb Ischemia reports efficacy and safety findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia

Drugs mentioned

• Ixmyelocel-T (Ixmyelocel-T)

Snippet

Sponsor: Vericel Corporation | Conditions: Critical Limb Ischemia | Phase 3 | Status: COMPLETED